|
Palifermin
resources
|
|
|
|
|
|
DRUG INFO
Palifermin
Drug Name:
Palifermin
Indication: For treatment of mucositis (mouth sores)
Pharmacology: Used in the prevention or treatment of oral mucoscitis (mouth ulcers arising from chemotherapy), Kepivance binds to the human keratinocyte growth factor (KGF) receptor on buccal cell surfaces. Kepivance acts as both a cell growth and survival factor by stimulating epithelial cell proliferation, differentiation, and migration around the tongue and mouth. The KGF receptor is found on many tissues particularly around the tongue, esophagus, salivary gland and other gastro-intestinal tract organs.
Mechanism Of Action: Kepivance binds to the human keratinocyte growth factor (KGF) receptor found on buccal cell surfaces. The binding activates a Ras-MapK (Map kinase) signaling pathway which leads to the transcriptional activation of many proteins important for cell growth and survival.
Drug Category: Antimucositis Agents
Brand Names/Synonyms: Keratinocyte growth factor precursor;KGF;Fibroblast growth factor- 7;FGF-7;HBGF-7; Kepivance (Amgen Inc)
Dosage Forms: Not Available
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Human keratinocyte growth factor
Chemical Formula: C721H1142N202O204S9
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: BIOD00042
CAS Registry Number: 162394-19-6
|
|
|
|
|
|
Palifermin News
(When available)
Special feature: cardiovascular-kidney interactions in health and ... Dec 29, 2005
AJP-Regul Integr Comp Physiology (subscription) ...function. Fibroblast growth factor-2 (FGF-2) is released by damaged endothelial cells and accumulates in patients with HIV/HUS. ...
Roswell Park Research Presented at National Hematology Meeting Dec 21, 2005
Newswise (press release) ...finding provides molecular evidence that heparins exert significant anti-angiogenic effect by directly sequestering fibroblast growth factor from receptors on ...
CuraGen Announces Preliminary Top-line Phase II Results on ... Dec 13, 2005
Yahoo! News (press release) Velafermin, also known as fibroblast growth factor-20 (FGF-20) or CG53135, is a novel protein therapeutic, discovered by CuraGen, that appears to promote both ...
CuraGen Announces Preliminary Top-line Phase II Results on ... Dec 13, 2005
PR Newswire (press release), Background on Oral Mucositis (OM) and Velafermin (CG53135) Velafermin, also known as fibroblast growth factor-20 (FGF-20) or CG53135, is a novel protein ...
|
|
|
